• Something wrong with this record ?

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients

K. Fellows, T. Uher, RW. Browne, B. Weinstock-Guttman, D. Horakova, H. Posova, M. Vaneckova, Z. Seidl, J. Krasensky, M. Tyblova, E. Havrdova, R. Zivadinov, M. Ramanathan,

. 2015 ; 56 (10) : 2010-2018. [pub] 20150804

Language English Country United States

Document type Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16028327

Grant support
NT13108 MZ0 CEP Register

The purpose of this work was to investigate the associations of serum cholesterol and apolipoproteins with measures of blood-brain barrier (BBB) permeability and CNS inflammation following the first clinical demyelinating event. This study included 154 patients [67% female; age, 29.5 ± 8.2 years (mean ± SD)] enrolled in a multi-center study of interferon β1-a treatment following the first demyelinating event. Blood and cerebrospinal fluid (CSF) were obtained at screening prior to treatment. A comprehensive serum lipid profile and multiple surrogate markers of BBB breakdown and CNS immune activity were obtained. Higher levels of serum HDL cholesterol (HDL-C) and ApoA-I were associated with lower CSF total protein level, CSF albumin level, albumin quotient, and CSF IgG level (all P ≤ 0.001 for HDL-C and all P < 0.01 for ApoA-I). HDL-C was also associated with CSF CD80+ (P < 0.001) and with CSF CD80+CD19+ (P = 0.007) cell frequencies. Higher serum HDL is associated with lower levels of BBB injury and decreased CD80+ and CD80+CD19+ cell extravasation into the CSF. HDL may potentially inhibit the initiation and/or maintenance of pathogenic BBB injury following the first demyelinating event.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16028327
003      
CZ-PrNML
005      
20181022114207.0
007      
ta
008      
161005s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1194/jlr.M060970 $2 doi
024    7_
$a 10.1194/jlr.M060970 $2 doi
035    __
$a (PubMed)26243484
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fellows, Kelly $u Departments of Pharmaceutical Sciences, State University of New York, Buffalo, NY.
245    10
$a Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients / $c K. Fellows, T. Uher, RW. Browne, B. Weinstock-Guttman, D. Horakova, H. Posova, M. Vaneckova, Z. Seidl, J. Krasensky, M. Tyblova, E. Havrdova, R. Zivadinov, M. Ramanathan,
520    9_
$a The purpose of this work was to investigate the associations of serum cholesterol and apolipoproteins with measures of blood-brain barrier (BBB) permeability and CNS inflammation following the first clinical demyelinating event. This study included 154 patients [67% female; age, 29.5 ± 8.2 years (mean ± SD)] enrolled in a multi-center study of interferon β1-a treatment following the first demyelinating event. Blood and cerebrospinal fluid (CSF) were obtained at screening prior to treatment. A comprehensive serum lipid profile and multiple surrogate markers of BBB breakdown and CNS immune activity were obtained. Higher levels of serum HDL cholesterol (HDL-C) and ApoA-I were associated with lower CSF total protein level, CSF albumin level, albumin quotient, and CSF IgG level (all P ≤ 0.001 for HDL-C and all P < 0.01 for ApoA-I). HDL-C was also associated with CSF CD80+ (P < 0.001) and with CSF CD80+CD19+ (P = 0.007) cell frequencies. Higher serum HDL is associated with lower levels of BBB injury and decreased CD80+ and CD80+CD19+ cell extravasation into the CSF. HDL may potentially inhibit the initiation and/or maintenance of pathogenic BBB injury following the first demyelinating event.
650    _2
$a dospělí $7 D000328
650    _2
$a apolipoproteiny $x krev $x mok mozkomíšní $7 D001053
650    _2
$a biologické markery $x krev $x mok mozkomíšní $7 D015415
650    _2
$a hematoencefalická bariéra $x účinky léků $x metabolismus $x patologie $7 D001812
650    _2
$a HDL-cholesterol $x krev $7 D008076
650    _2
$a demyelinizační nemoci $7 D003711
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x krev $x mok mozkomíšní $7 D007249
650    _2
$a interferon beta $x terapeutické užití $7 D016899
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a roztroušená skleróza $x krev $x mok mozkomíšní $x farmakoterapie $x patologie $7 D009103
650    _2
$a nemoci nervového systému $x krev $x mok mozkomíšní $7 D009422
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Uher, Tomáš $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. $7 xx0189534
700    1_
$a Browne, Richard W $u Biotechnical and Clinical Laboratory Sciences, State University of New York, Buffalo, NY.
700    1_
$a Weinstock-Guttman, Bianca $u Neurology, State University of New York, Buffalo, NY.
700    1_
$a Horáková, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. $7 xx0076527
700    1_
$a Posová, Helena, $u Institute of Immunology and Microbiology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. $d 1963- $7 xx0060265
700    1_
$a Vaněčková, Manuela, $u Department of Radiology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. $d 1973- $7 mzk2007377403
700    1_
$a Seidl, Zdeněk, $u Department of Radiology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. $d 1950- $7 mzk2004258727
700    1_
$a Krásenský, Jan $u Department of Radiology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. $7 xx0096156
700    1_
$a Týblová, Michaela $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. $7 xx0121850
700    1_
$a Kubala Havrdová, Eva, $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic. $d 1955- $7 nlk19990073204
700    1_
$a Zivadinov, Robert $u Neurology, State University of New York, Buffalo, NY Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY.
700    1_
$a Ramanathan, Murali $u Departments of Pharmaceutical Sciences, State University of New York, Buffalo, NY Neurology, State University of New York, Buffalo, NY.
773    0_
$w MED00002766 $t Journal of lipid research $x 1539-7262 $g Roč. 56, č. 10 (2015), s. 2010-2018
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26243484 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20181022114712 $b ABA008
999    __
$a ok $b bmc $g 1166641 $s 952957
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 56 $c 10 $d 2010-2018 $e 20150804 $i 1539-7262 $m Journal of lipid research $n J Lipid Res $x MED00002766
GRA    __
$a NT13108 $p MZ0
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options